Pieris inks a li­cens­ing deal for Japan; Kindler joins Phar­ma Two B board with $30M raise; Am­pio plots new pain study

→ Boston-based Pieris $PIRS has op­tioned a li­cens­ing pact giv­ing AS­KA Phar­ma­ceu­ti­cal de­vel­op­ment and com­mer­cial­iza­tion rights for the ane­mia drug PRS-080 in Japan and cer­tain oth­er Asian mar­kets. Pieris gets a $2.75 mil­lion op­tion pay­ment on the deal, and if AS­KA agrees to for­mal­ly sign on af­ter look­ing over Phase IIa da­ta, then Pieris will be in line for up to $80 mil­lion in mile­stones. “We are pleased to have found a very com­mit­ted part­ner for PRS-080 in a key Asian mar­ket,” said Stephen Yo­der, the CEO of Pieris. “Im­por­tant­ly, this deal en­ables us to in­vest in im­prov­ing drug man­u­fac­tur­ing ef­fi­cien­cies while con­duct­ing our Phase 2a tri­al to en­able seam­less drug sup­ply for fu­ture clin­i­cal stud­ies by AS­KA and oth­er part­ners we may seek in oth­er ter­ri­to­ries, as we fo­cus our pro­pri­etary pipeline in im­munol­o­gy-re­lat­ed ar­eas for long-term val­ue cre­ation.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.